

Michel Obeid

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8184091/publications.pdf>

Version: 2024-02-01

30
papers

9,045
citations

516710

16
h-index

677142

22
g-index

30
all docs

30
docs citations

30
times ranked

13086
citing authors

#	ARTICLE	IF	CITATIONS
1	Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients. <i>JAMA Oncology</i> , 2022, 8, e220446.	7.1	48
2	Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis. <i>Journal of Thoracic Oncology</i> , 2021, 16, 318-326.	1.1	24
3	Reactivation of IgA vasculitis after COVID-19 vaccination. <i>Lancet Rheumatology</i> , The, 2021, 3, e617.	3.9	54
4	⁶⁸ Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis. , 2021, 9, e003594.		30
5	Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. , 2021, 9, e003277.		49
6	Cytokine-directed therapy with tocilizumab for immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosis. <i>Annals of Oncology</i> , 2020, 31, 1775-1778.	1.2	19
7	Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis. <i>Annals of Oncology</i> , 2020, 31, 1273-1275.	1.2	44
8	Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. , 2020, 8, e000604.		98
9	Personalized treatment of immune-related adverse events – balance is required. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 517-517.	27.6	7
10	A Diffuse Medullary Hypercapitation With No Bone Lesion. <i>JAMA Oncology</i> , 2020, 6, 291.	7.1	0
11	Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. <i>Annals of Oncology</i> , 2020, 31, 724-744.	1.2	129
12	COVID-19 and lung cancer: risks, mechanisms and treatment interactions. , 2020, 8, e000892.		43
13	Personalized treatment of immune checkpoint inhibitor-related severe hemophagocytic lymphohistiocytosis (HLH).. <i>Journal of Clinical Oncology</i> , 2020, 38, e15079-e15079.	1.6	0
14	Long-lasting, irreversible and late-onset immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs): A real-world data analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15095-e15095.	1.6	3
15	Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 563-580.	27.6	1,235
16	New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. <i>Lancet Oncology</i> , The, 2019, 20, e54-e64.	10.7	149
17	Generating the Abscopal Effect by Combining Proapoptotic Peptides With IL-12-Based Immunotherapy. <i>Neoplasia</i> , 2018, 20, 193-196.	5.3	2
18	A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy. , 2018, 6, 156.		58

#	ARTICLE	IF	CITATIONS
19	A severe case of neuro-Sjögren's syndrome induced by pembrolizumab. , 2018, 6, 110.		40
20	Can local radiotherapy and IL-12 synergise to overcome the immunosuppressive tumor microenvironment and allow "in situ tumor vaccination"? Cancer Immunology, Immunotherapy, 2017, 66, 833-840.	4.2	21
21	Skin-draining lymph node priming is sufficient to induce sterile immunity against pre-erythrocytic malaria. EMBO Molecular Medicine, 2013, 5, 250-263.	6.9	33
22	Anticancer activity of targeted proapoptotic peptides and chemotherapy is highly improved by targeted cell surface calreticulin inducer peptides. Molecular Cancer Therapeutics, 2009, 8, 2693-2707.	4.1	15
23	ERP57 Membrane Translocation Dictates the Immunogenicity of Tumor Cell Death by Controlling the Membrane Translocation of Calreticulin. Journal of Immunology, 2008, 181, 2533-2543.	0.8	87
24	Leveraging the Immune System during Chemotherapy: Moving Calreticulin to the Cell Surface Converts Apoptotic Death from "Silent" to Immunogenic. Cancer Research, 2007, 67, 7941-7944.	0.9	134
25	Calreticulin exposure dictates the immunogenicity of cancer cell death. Nature Medicine, 2007, 13, 54-61.	30.7	2,580
26	Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nature Medicine, 2007, 13, 1050-1059.	30.7	2,657
27	Ecto-calreticulin in immunogenic chemotherapy. Immunological Reviews, 2007, 220, 22-34.	6.0	183
28	Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. Journal of Molecular Medicine, 2007, 85, 1069-1076.	3.9	68
29	Immunogenic chemotherapy: discovery of a critical protein through proteomic analyses of tumor cells. Cancer Genomics and Proteomics, 2007, 4, 65-70.	2.0	11
30	Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. Journal of Experimental Medicine, 2005, 202, 1691-1701.	8.5	1,224